Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancer

Foluso O. Ademuyiwa, Kathy Miller

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Angiogenesis plays a central role in the development of metastasis in breast cancer. Recent results of large randomized trials show clinically significant improvements in outcomes with the use of bevacizumab in patients with metastatic breast cancer, leading to approval by European and US regulatory agencies. Several other antiangiogenic strategies are in various stages of development. This review discusses the results of recent clinical trials and novel mechanisms of inhibiting angiogenesis, resistance mechanisms, and toxicities; and raises key challenges that face optimal use and development of antiangiogenic agents in breast cancer.

Original languageEnglish (US)
JournalClinical Breast Cancer
Volume8
Issue numberSUPPL. 4
DOIs
StatePublished - 2008
Externally publishedYes

Fingerprint

Breast Neoplasms
Angiogenesis Inhibitors
Therapeutics
Clinical Trials
Neoplasm Metastasis
Bevacizumab

Keywords

  • Bevacizumab
  • Pazopanib
  • Tamoxifen
  • Tyrosine kinase inhibitors
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancer. / Ademuyiwa, Foluso O.; Miller, Kathy.

In: Clinical Breast Cancer, Vol. 8, No. SUPPL. 4, 2008.

Research output: Contribution to journalArticle

@article{a05046ae0b974a54a023ade51b776c5f,
title = "Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancer",
abstract = "Angiogenesis plays a central role in the development of metastasis in breast cancer. Recent results of large randomized trials show clinically significant improvements in outcomes with the use of bevacizumab in patients with metastatic breast cancer, leading to approval by European and US regulatory agencies. Several other antiangiogenic strategies are in various stages of development. This review discusses the results of recent clinical trials and novel mechanisms of inhibiting angiogenesis, resistance mechanisms, and toxicities; and raises key challenges that face optimal use and development of antiangiogenic agents in breast cancer.",
keywords = "Bevacizumab, Pazopanib, Tamoxifen, Tyrosine kinase inhibitors, Vascular endothelial growth factor",
author = "Ademuyiwa, {Foluso O.} and Kathy Miller",
year = "2008",
doi = "10.3816/CBC.2008.s.011",
language = "English (US)",
volume = "8",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancer

AU - Ademuyiwa, Foluso O.

AU - Miller, Kathy

PY - 2008

Y1 - 2008

N2 - Angiogenesis plays a central role in the development of metastasis in breast cancer. Recent results of large randomized trials show clinically significant improvements in outcomes with the use of bevacizumab in patients with metastatic breast cancer, leading to approval by European and US regulatory agencies. Several other antiangiogenic strategies are in various stages of development. This review discusses the results of recent clinical trials and novel mechanisms of inhibiting angiogenesis, resistance mechanisms, and toxicities; and raises key challenges that face optimal use and development of antiangiogenic agents in breast cancer.

AB - Angiogenesis plays a central role in the development of metastasis in breast cancer. Recent results of large randomized trials show clinically significant improvements in outcomes with the use of bevacizumab in patients with metastatic breast cancer, leading to approval by European and US regulatory agencies. Several other antiangiogenic strategies are in various stages of development. This review discusses the results of recent clinical trials and novel mechanisms of inhibiting angiogenesis, resistance mechanisms, and toxicities; and raises key challenges that face optimal use and development of antiangiogenic agents in breast cancer.

KW - Bevacizumab

KW - Pazopanib

KW - Tamoxifen

KW - Tyrosine kinase inhibitors

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=60849136361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60849136361&partnerID=8YFLogxK

U2 - 10.3816/CBC.2008.s.011

DO - 10.3816/CBC.2008.s.011

M3 - Article

VL - 8

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - SUPPL. 4

ER -